SLC5A2 and hydrops fetalis: SGLT-2 inhibitors were shown to provide significant cardiovascular benefits among subjects with established HF with reduced ejection fraction (HFrEF) by significantly decreasing the risk for cardiovascular death and hospitalization due to worsening HF [19,20], while they were also shown to significantly decrease the risk for HF decompensation among subjects with HFpEF without affecting the overall risk for cardiovascular death [21,22].